Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$108.09 USD

108.09
1,053,644

-0.90 (-0.83%)

Updated Jul 29, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Walgreens Boots (WBA) Omnichannel Aids Growth Amid Cost Woes

by Zacks Equity Research

The continued acceleration of Walgreens' (WBA) omnichannel offerings and a significant rise in MyWalgreens membership are notable upsides in recent times.

Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.

Change Healthcare (CHNG) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI

by Zacks Equity Research

Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.

Here's Why You Must Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Masimo's (MASI) PVi Favored by New Study for Pediatric Patients

by Zacks Equity Research

Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs.

NextGen Healthcare's (NXGN) Solutions Selected by MHHC

by Zacks Equity Research

NextGen Healthcare's (NXGN) solutions get chosen by MHHC that can help serve the latter's rapidly growing community efficiently.

Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.

What's in Store for Canopy Growth (CGC) in Q4 Earnings?

by Zacks Equity Research

Product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to have driven Canopy Growth's (CGC) Q4 top line.

Here's Why You Should Retain Change Healthcare (CHNG) Stock

by Zacks Equity Research

Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.

Thermo Fisher (TMO) to Advance Precision Medicine in Qatar

by Zacks Equity Research

Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.

What's in the Cards for Medtronic (MDT) in Q4 Earnings?

by Zacks Equity Research

Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.

Can Masimo (MASI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

PerkinElmer (PKI) Boosts Genomic Testing Portfolio With urWGS

by Zacks Equity Research

PerkinElmer's (PKI) urWGS will improve outcomes for critically ill patients in NICUs and PICUs.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.

NextGen Healthcare (NXGN) Q4 Earnings Miss Mark, Revenues Beat

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal fourth-quarter earnings reflect strength in its Recurring revenues.

BD (BDX) Introduces New Molecular Diagnostic Platform in US

by Zacks Equity Research

BD's (BDX) new fully-automated, high-throughput infectious disease molecular diagnostics platform in the United States to aid lab technicians in prioritizing higher value work.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

AMN Healthcare's (AMN) New Buyout to Aid Healthcare Staffing

by Zacks Equity Research

AMN Healthcare's (AMN) acquisition of Connetics USA is expected to significantly boost its Nurse and Allied Solutions segment globally.

Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.

Wall Street Analysts Think Masimo (MASI) Could Surge 135%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Masimo (MASI) points to a 134.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection

by Zacks Equity Research

BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.